Le Lézard
Classified in: Health, Science and technology
Subjects: SLS, ACC

Cantargia Publishes Interim Report for Third Quarter of 2018


STOCKHOLM, Nov. 15, 2018 /PRNewswire/ --

Cantargia AB's interim report for the third quarter of 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Significant events in the third quarter

Clinical

Patents

Change of list

Significant events after the end of the period

Financial information

First nine months (1 Jan 2018 ? 30 Sep 2018)

Third quarter (1 July 2018 ? 30 Sep 2018)

For further information, please contact
Göran Forsberg, CEO
Telephone: +46(0)46-275-62-60
E-mail: [email protected]

This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on November 15 2018.

About us
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy. Cantargia's other project, CANxx, is in the research phase and is aiming to develop a IL1RAP binding antibody optimised for the treatment of autoimmune and inflammatory diseases.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/cantargia-ab/r/cantargia-publishes-interim-report-for-third-quarter-of-2018,c2672242

The following files are available for download:

http://mb.cision.com/Main/7470/2672242/944872.pdf

PDF

http://mb.cision.com/Public/7470/2672242/93f0d8359fc9e72f.pdf

Pressmeddelande-delarsrapport eng final

 


These press releases may also interest you

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:15
The Micro-electro-mechanical System (MEMS) market is projected to grow from USD 16.5 billion in 2024 and is estimated to reach USD 24.2 billion by 2029; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.9% from 2024 to 2029...

at 10:12
NerdsToGo®, a leading information technology (IT) solutions and technology repair services franchise for both business and home, announced today plans for its strategic expansion throughout the greater Chicago area with 20 new territories available...

at 10:11
TeachTown, a leading provider of special education curriculum for students with moderate to severe disabilities, is pleased to announce that its K-12 standards-based, adapted core curriculum, enCORE, has been named a finalist in 2 categories of the...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....



News published on and distributed by: